Expert Opinion on Drug Safety

1

Safety concerns with the long-term management of osteoporosis

Reginster, Jean-Yves, Pelousse, Franz, Bruyère, Olivier

Journal:

Year:

2013

Language:

english

File:

PDF, 321 KB

english, 2013

2

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

Scheen, Andre

Journal:

Expert Opinion on Drug Safety

Year:

2013

Language:

english

File:

PDF, 363 KB

english, 2013

3

Drug-induced parkinsonism

López-Sendón, José, Mena, Maria A, G de Yébenes, Justo

Journal:

Expert Opinion on Drug Safety

Year:

2013

Language:

english

File:

PDF, 245 KB

english, 2013

4

The safety and efficacy of apixaban: where do we stand in 2013?

de Souza Brito, Flavio, Lopes, Renato D, Alexander, John H

Journal:

Expert Opinion on Drug Safety

Year:

2013

Language:

english

File:

PDF, 280 KB

english, 2013

5

Risks associated with the therapeutic use of fluoroquinolones

Stahlmann, Ralf, Lode, Hartmut M

Journal:

Expert Opinion on Drug Safety

Year:

2013

Language:

english

File:

PDF, 309 KB

english, 2013

6

Potential nephroprotective effects of l- carnitine against drug-induced nephropathy: a review of literature

Jafari, Atefeh, Dashti-Khavidaki, Simin, Khalili, Hossein, Lessan-Pezeshki, Mahboob

Journal:

Expert Opinion on Drug Safety

Year:

2013

Language:

english

File:

PDF, 361 KB

english, 2013

7

Efficacy and safety of mipomersen sodium (Kynamro)

Hovingh, Kees, Besseling, Joost, Kastelein, John

Journal:

Expert Opinion on Drug Safety

Year:

2013

Language:

english

File:

PDF, 544 KB

english, 2013

8

Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials

Essex, Margaret Noyes, Zhang, Richard Y, Berger, Manuela F, Upadhyay, Sameer, Park, Peter W

Journal:

Expert Opinion on Drug Safety

Year:

2013

Language:

english

File:

PDF, 332 KB

english, 2013

9

Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease

Solís-García del Pozo, Julián, Mínguez-Mínguez, Sara, de Groot, Piet WJ, Jordán, Joaquín

Journal:

Expert Opinion on Drug Safety

Year:

2013

Language:

english

File:

PDF, 280 KB

english, 2013

10

Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain

Castellano, Daniel, Duh, Mei Sheng, Korves, Caroline, Suthoff, Ellison Dial, Neary, Maureen, Hernández Pastor, Luis Javier, Bellmunt, Joaquim

Journal:

Expert Opinion on Drug Safety

Year:

2013

Language:

english

File:

PDF, 225 KB

english, 2013

12

Safety evaluation of leflunomide in rheumatoid arthritis

I Keen, Helen, Conaghan, Philip G, Tett, Susan E

Journal:

Expert Opinion on Drug Safety

Year:

2013

Language:

english

File:

PDF, 287 KB

english, 2013

13

2012 Annual Meeting of the Safety Pharmacology Society: spotlight on targeted oncology medicines

Cavero, Icilio

Journal:

Expert Opinion on Drug Safety

Year:

2013

Language:

english

File:

PDF, 318 KB

english, 2013

Volume 12; Issue 4

Safety concerns with the long-term management of osteoporosis

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

Drug-induced parkinsonism

The safety and efficacy of apixaban: where do we stand in 2013?

Risks associated with the therapeutic use of fluoroquinolones

Potential nephroprotective effects of l- carnitine against drug-induced nephropathy: a review of literature

Efficacy and safety of mipomersen sodium (Kynamro)

Safety of celecoxib compared with placebo and non-selective NSAIDs: cumulative meta-analysis of 89 randomized controlled trials

Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating Parkinson's disease

Related articles

Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain

Safety evaluation of leflunomide in rheumatoid arthritis

2012 Annual Meeting of the Safety Pharmacology Society: spotlight on targeted oncology medicines